Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

360 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study).
Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, Nomura A, Yoshida S, Nishimoto N. Nakaoka Y, et al. Among authors: nishimoto n. Ann Rheum Dis. 2018 Mar;77(3):348-354. doi: 10.1136/annrheumdis-2017-211878. Epub 2017 Nov 30. Ann Rheum Dis. 2018. PMID: 29191819 Free PMC article. Clinical Trial.
Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study.
Nakaoka Y, Isobe M, Tanaka Y, Ishii T, Ooka S, Niiro H, Tamura N, Banno S, Yoshifuji H, Sakata Y, Kawakami A, Atsumi T, Furuta S, Kohsaka H, Suzuki K, Hara R, Maejima Y, Tsukamoto H, Takasaki Y, Yamashita K, Okada N, Yamakido S, Takei S, Yokota S, Nishimoto N. Nakaoka Y, et al. Among authors: nishimoto n. Rheumatology (Oxford). 2020 Sep 1;59(9):2427-2434. doi: 10.1093/rheumatology/kez630. Rheumatology (Oxford). 2020. PMID: 31951279 Free PMC article. Clinical Trial.
Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extension study in Japan.
Yokota S, Imagawa T, Mori M, Miyamae T, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T. Yokota S, et al. Among authors: nishimoto n. Ann Rheum Dis. 2013 Apr;72(4):627-8. doi: 10.1136/annrheumdis-2012-202310. Epub 2012 Nov 30. Ann Rheum Dis. 2013. PMID: 23204515 Clinical Trial. No abstract available.
Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
Yokota S, Imagawa T, Mori M, Miyamae T, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T. Yokota S, et al. Among authors: nishimoto n. J Rheumatol. 2014 Apr;41(4):759-67. doi: 10.3899/jrheum.130690. Epub 2014 Mar 15. J Rheumatol. 2014. PMID: 24634205 Clinical Trial.
Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study.
Ogata A, Amano K, Dobashi H, Inoo M, Ishii T, Kasama T, Kawai S, Kawakami A, Koike T, Miyahara H, Miyamoto T, Munakata Y, Murasawa A, Nishimoto N, Ogawa N, Ojima T, Sano H, Shi K, Shono E, Suematsu E, Takahashi H, Tanaka Y, Tsukamoto H, Nomura A; MUSASHI Study Investigators. Ogata A, et al. Among authors: nishimoto n. J Rheumatol. 2015 May;42(5):799-809. doi: 10.3899/jrheum.140665. Epub 2015 Apr 1. J Rheumatol. 2015. PMID: 25834203 Clinical Trial.
Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study.
Ishiguro N, Atsumi T, Harigai M, Mimori T, Nishimoto N, Sumida T, Takeuchi T, Tanaka Y, Nakasone A, Takagi N, Yamanaka H. Ishiguro N, et al. Among authors: nishimoto n. Mod Rheumatol. 2017 Mar;27(2):217-226. doi: 10.1080/14397595.2016.1206507. Epub 2016 Jul 14. Mod Rheumatol. 2017. PMID: 27414105
Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.
Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T. Yokota S, et al. Among authors: nishimoto n. Lancet. 2008 Mar 22;371(9617):998-1006. doi: 10.1016/S0140-6736(08)60454-7. Lancet. 2008. PMID: 18358927 Clinical Trial.
Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis.
Imagawa T, Yokota S, Mori M, Miyamae T, Takei S, Imanaka H, Nerome Y, Iwata N, Murata T, Miyoshi M, Nishimoto N, Kishimoto T. Imagawa T, et al. Among authors: nishimoto n. Mod Rheumatol. 2012 Feb;22(1):109-15. doi: 10.1007/s10165-011-0481-0. Epub 2011 Jun 12. Mod Rheumatol. 2012. PMID: 21667343 Clinical Trial.
Abnormal expression of the genes involved in cytokine networks and mitochondrial function in systemic juvenile idiopathic arthritis identified by DNA microarray analysis.
Ishikawa S, Mima T, Aoki C, Yoshio-Hoshino N, Adachi Y, Imagawa T, Mori M, Tomiita M, Iwata N, Murata T, Miyoshi M, Takei S, Aihara Y, Yokota S, Matsubara K, Nishimoto N. Ishikawa S, et al. Among authors: nishimoto n. Ann Rheum Dis. 2009 Feb;68(2):264-72. doi: 10.1136/ard.2007.079533. Epub 2008 Apr 3. Ann Rheum Dis. 2009. PMID: 18388159
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab.
Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Murata N, van der Heijde D, Kishimoto T. Nishimoto N, et al. Ann Rheum Dis. 2007 Sep;66(9):1162-7. doi: 10.1136/ard.2006.068064. Epub 2007 May 7. Ann Rheum Dis. 2007. PMID: 17485422 Free PMC article. Clinical Trial.
360 results